OliX Pharmaceuticals said Monday that Professor Demetrios G. Vavvas, one of the world leaders in the field of ophthalmology, has joined its scientific advisory board (SAB).
|Professor Demetrios G. Vavvas|
Professor Vavvas currently serves as the associate professor of ophthalmology at Harvard Medical School and Monte J. Wallace Ophthalmology Chair in Retina at the Massachusetts Eye and Ear Infirmary. He has received more than 32 awards and honors and is the author of over 183 publications and cited about 10,400 times by others.
“I am interested in OliX's cp-asiRNA platform technology which is optimal for the development of ocular therapeutics,” Professor Vavvas said. “I look forward to helping the applications of the technology on ocular diseases to benefit eye patients.”
OliX CEO Lee Dong-ki also said, “We are very pleased to announce that Professor Vavvas has joined our SAB as he is a distinguished scientific expert in ophthalmology and has pioneered research in diabetic retinopathy, ocular tumors, and the ‘dry’ form of age-related macular degeneration (AMD).”
The company plans to focus on developing ocular diseases with its SAB, and will advance its innovative RNAi ocular therapeutics toward commercialization, Lee added.
<© Korea Biomedical Review, All rights reserved.>